A Phase 4 interventional study of Zofenopril and Amlodipine in Hypertension, sponsored by Menarini International Operations Luxembourg SA. Completed at 1 site in Hungary. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by Menarini International Operations Luxembourg SA (part of Menarini Group) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 72nd largest by enrollment of the 186 interventional ones that give a count, is one of 4 that started in 2021, is one of 80 in phase 4, and was the 175th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 277 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
This study is registered under Menarini International Operations Luxembourg SA, one of the names counted as Menarini Group. Under that name alone:
Menarini International Operations Luxembourg SA is the lead sponsor of 8 studies on the registry; none are open to participants now.
Menarini Group has 8 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Zofenopril 30 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment in patients with uncontrolled BP previously treated with Zofenopril or Amlodipine (5 mg) monotherapies for at least 4 weeks.
Approximately 290 patients are planned to be screened to ensure at least 216 patients complete the run-in period and start with the assessment period.
Patients with Grade 1-2 hypertensive patients (blood pressure [BP] ranging from ≥140/90 mmHg to ≤179/109 mmHg) on treatment with any angiotensin converting enzyme inhibitors (ACE-i) including Zofenopril (ZOF)30 mg or with calcium channel blockers (CCBs) including Amlodipine (AML)5 mg will be screened for eligibility (Visit 1).
Allowed CCBs: Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine. Patients treated with other dosages of ZOF (other than 30 mg) are not allowed to be screened. After screening, on the same day, eligible patients, will enter into a 4-week run-in period, during which patients on other ACE-i will be assigned to monotherapy with ZOF 30 mg while patients on CCBs will be assigned to monotherapy with AML 5 mg for 4 weeks. Patients with on-going treatment zofenopril 30 mg and amlodipine 5mg will continue on the same treatment for 4 weeks.
After the run-in period (4 weeks ± 2 days), BP will be further assessed (Visit 2), if BP levels are over the defined controlled target goal, sitting Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) >130/80 mmHg, treatment is well tolerated and adherence to the treatments ranges from 80% to 120%, patients will enter the assessment period, where they will be assigned to the extemporaneous combination of ZOF 30 mg and AML 5 mg. At Visit 2 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension will be withdrawn from the study.
If patients, at Visit 2, after the run-in period, have a controlled BP (sitting SBP/DBP≤130/80 mmHg) or do not tolerate the treatment or have an adherence range below 80% or superior to 120%, they will be withdrawn from the study.
The patients will be assessed for further 8 weeks (assessment period). After 4 weeks ± 2 days from Visit 2,during the assessment period patients receiving the extemporaneous combination of ZOF 30 mg and AML 5 mg, will be further evaluated (Visit 3): controlled patients (sitting SBP/DBP ≤130/80 mmHg) will continue the same extemporaneous combination for additional 4 weeks ± 2 days, while uncontrolled patients (sitting SBP/DBP >130/80 mmHg) will be up-titrated from ZOF/AML 30/5 mg to ZOF/AML 30/10 mg for further 4 weeks ± 2 days. At Visit 3 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension will be withdrawn from the study. If patients at Visit 3, do not tolerate the extemporaneous combination treatment or they have an adherence range below 80% or superior to 120%, they will be withdrawn from the study.
At the end of the assessment period (8 weeks ± 4 days) at Visit 4, the anti-hypertensive effect of the extemporaneous combination (ZOF/AML 30/5 mg and ZOF/AML 30/10 mg) will be evaluated.
Efforts will be made to achieve 1:1 ratio in the enrolment of patients receiving any ACE-i or allowed CCBs (refer to section Subject Study Phases Duration for allowed CCBs). At Visit 2, a minimum of 45% of uncontrolled patients receiving treatment with ZOF 30 mg or AML 5 mg are required to enter the assessment period, in order to maintain a balance between the 2 treatments during the assessment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients are eligible to participate if not pregnant, or not breastfeeding and must refrain from donating or storing eggs. For females of : use of highly effective (e.g., method of birth control throughout the study period and for 4 weeks after study completion defined as a method which results in a failure rate of less than 1% per year) such as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose Phase (4 weeks): patients will be treated with Zofenopril 30 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
Drug: Zofenopril · Drug: Amlodipine
Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.
Drug: Zofenopril · Drug: Amlodipine
Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)
To assess the antihypertensive efficacy of the extemporaneous combination of Zofenopril (ZOF) 30 mg in combination with Amlodipine (AML) 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with Zofenopril or Amlodipine (5 mg) monotherapies for at least 4 weeks during run-in period.
Time frame: From Visit 2 (week 0) to Visit 4 (week 8) for a total of 8 weeks
| Milestone | Zofenopril 30mg | Amlodipine 5/10 mg |
|---|---|---|
| Started | 144 | 133 |
| Completed | 142 | 132 |
| Not completed | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Laboratory abnormal results | 1 | 0 |
To assess the antihypertensive efficacy of the extemporaneous combination of Zofenopril (ZOF) 30 mg in combination with Amlodipine (AML) 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with Zofenopril or Amlodipine (5 mg) monotherapies for at least 4 weeks during run-in period.
| mmHg | Combination Therapy Phase Zofenopril 30mg/Amlodipine 5 or 10 mg |
|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8) | -13.5 ± 8.31 |
Collected over From Informed Consent signature at screening visit (Visit 1) occurring 4 week previous than Baseline assessment (Week 0 - Visit 2) to last visit at Week 8 (Visit 4) for an average of 12 weeks. Furthermore patients having any ongoing Adverse Event/Serious Adverse Event at the end of the treatment (Week 8 - Visit 4), will be followed for further 2 weeks via a phone call to check about the status of the Adverse Events/Serious Adverse Events, extending the time frame to a total of 14 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zofenopril 30mg MONOTHERAPY PERIOD | 0/143 (0%) | 0/143 (0%) | 8/143 (5.6%) |
| Amlodipine 5 mg MONOTHERAPY PERIOD | 0/133 (0%) | 0/133 (0%) | 11/133 (8.3%) |
| Zofenopril 30mg/Amlodipine 5mg COMBINATION THERAPY PERIOD | 0/149 (0%) | 0/149 (0%) | 10/149 (6.7%) |
| Zofenopril 30mg/Amlodipine 10mg COMBINATION THERAPY PERIOD | 0/122 (0%) | 1/122 (0.8%) | 20/122 (16.4%) |
| Event | Zofenopril 30mg MONOTHERAPY PERIOD | Amlodipine 5 mg MONOTHERAPY PERIOD | Zofenopril 30mg/Amlodipine 5mg COMBINATION THERAPY PERIOD | Zofenopril 30mg/Amlodipine 10mg COMBINATION THERAPY PERIOD |
|---|---|---|---|---|
| Oesophageal food impactionGastrointestinal disorders | 0/143 | 0/133 | 0/149 | 1/122 |
| Event | Zofenopril 30mg MONOTHERAPY PERIOD | Amlodipine 5 mg MONOTHERAPY PERIOD | Zofenopril 30mg/Amlodipine 5mg COMBINATION THERAPY PERIOD | Zofenopril 30mg/Amlodipine 10mg COMBINATION THERAPY PERIOD |
|---|---|---|---|---|
| Respiratory tract infection viralInfections and infestations | 1/143 | 1/133 | 6/149 | 2/122 |
| COVID-19Infections and infestations | 1/143 | 4/133 | 0/149 | 4/122 |
| HeadacheNervous system disorders | 3/143 | 2/133 | 1/149 | 4/122 |
| Back painMusculoskeletal and connective tissue disorders | 0/143 | 0/133 | 1/149 | 4/122 |
| HyperuricemiaMetabolism and nutrition disorders | 0/143 | 0/133 | 1/149 | 2/122 |
| GastritisGastrointestinal disorders | 0/143 | 0/133 | 0/149 | 2/122 |
| NauseaGastrointestinal disorders | 0/143 | 0/133 | 0/149 | 2/122 |
| Dry MouthGastrointestinal disorders | 0/143 | 2/133 | 0/149 | 0/122 |
| AstheniaGeneral disorders | 1/143 | 2/133 | 0/149 | 0/122 |
| DizzinessNervous system disorders | 2/143 | 0/133 | 1/149 | 0/122 |
| Age, Continuous(years) | Zofenopril 30mg | Amlodipine 5/10 mg | Total |
|---|---|---|---|
| Mean | 51.1 ± 9.96 | 54.1 ± 9.03 | 52.3 ± 9.83 |
| Sex: Female, Male(Participants) | Zofenopril 30mg | Amlodipine 5/10 mg | Total |
|---|---|---|---|
| Female | 77 | 83 | 160 |
| Male | 67 | 50 | 117 |
| Ethnicity (NIH/OMB)(Participants) | Zofenopril 30mg | Amlodipine 5/10 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 144 | 133 | 277 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Apr 2022, 6 months.
Results were first posted in Oct 2024, 2 years 5 months after primary completion.
Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 6 months is below that.
Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zofenopril · Amlodipine
Menarini International Operations Luxembourg SA →